Chemed (NYSE:CHE) CEO Sells $1,075,800.00 in Stock

Chemed Corporation (NYSE:CHE) CEO Kevin Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $537.90, for a total transaction of $1,075,800.00. Following the completion of the transaction, the chief executive officer owned 82,220 shares in the company, valued at approximately $44,226,138. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Chemed Stock Down 1.4%

Chemed stock opened at $526.43 on Friday. The firm has a 50 day moving average price of $514.46 and a 200-day moving average price of $465.08. The company has a quick ratio of 1.08, a current ratio of 1.11 and a debt-to-equity ratio of 0.27. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $562.24. The company has a market capitalization of $6.85 billion, a P/E ratio of 25.19, a P/E/G ratio of 2.01 and a beta of 0.50.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 EPS for the quarter, topping analysts’ consensus estimates of $6.44 by $0.31. Chemed had a net margin of 10.61% and a return on equity of 35.18%. The company had revenue of $690.94 million for the quarter, compared to analysts’ expectations of $685.04 million. During the same quarter in the previous year, the firm posted $5.27 EPS. Chemed’s revenue was up 10.6% on a year-over-year basis. As a group, equities analysts predict that Chemed Corporation will post 24.05 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CHE. Wall Street Zen raised Chemed from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 10th. Bank of America reissued a “neutral” rating on shares of Chemed in a report on Wednesday, July 29th. Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and boosted their price objective for the company from $520.00 to $620.00 in a research note on Wednesday, October 28th. UBS Group upped their price objective on shares of Chemed from $650.00 to $675.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Finally, Royal Bank Of Canada increased their target price on shares of Chemed from $548.00 to $585.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 29th. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $603.00.

Institutional Investors Weigh In On Chemed

A number of hedge funds and other institutional investors have recently bought and sold shares of CHE. Quantbot Technologies LP bought a new stake in Chemed during the 2nd quarter worth approximately $1,726,000. The Manufacturers Life Insurance Company purchased a new stake in Chemed in the 2nd quarter worth approximately $4,413,000. Lone Peak Global Investors LLC boosted its holdings in Chemed by 38.1% in the 2nd quarter. Lone Peak Global Investors LLC now owns 37,099 shares of the company’s stock valued at $17,279,000 after purchasing an additional 10,226 shares during the period. Hsbc Holdings PLC boosted its holdings in Chemed by 41.7% in the 2nd quarter. Hsbc Holdings PLC now owns 12,346 shares of the company’s stock valued at $5,729,000 after purchasing an additional 3,632 shares during the period. Finally, Amundi grew its position in shares of Chemed by 51.5% during the 2nd quarter. Amundi now owns 53,856 shares of the company’s stock valued at $25,083,000 after purchasing an additional 18,301 shares in the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Company Profile

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.